Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc.HSAQ · Entity 434 | Director | August 03, 2020 | August 10, 2020 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director · CHIEF EXECUTIVE OFFICER | January 31, 2023 | February 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Orchestra BioMed Holdings, Inc.
Report date August 03, 2020 · Filed August 10, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,261 |
Reported balance
Holding disclosure · report date 2020-08-03 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 22,261 |
PTC THERAPEUTICS, INC.
Report date January 31, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 166,962 |
Reported balance
After 2023-01-31 transaction · row 1
1 source rowRow 1 · 2023-01-31 · Sale · Disposed 2,320 · Balance 166,962 F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 54,903 |
Reported balance
After 2023-01-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-01-31 · Sale · Disposed 301 · Balance 54,903 F2: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,214 RSUs from a January 29, 2020 grant of 4,855 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs.
F2: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,214 RSUs from a January 29, 2020 grant of 4,855 RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 22,511 | $10.85 | $244,244.35 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · nonDerivative · entry 7 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 11, 2020. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 50,015 | $50.10 | $2,505,851.53 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · nonDerivative · entry 6 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.12 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 50,015 | $10.85 | $542,662.75 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · nonDerivative · entry 5 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. Read SEC document |
| October 05, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 54,560 | $10.85 Strike: $10.85 | $591,976.00 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · derivative · entry 12 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,134 Underlying: Common Stock · 54,560 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 11, 2020. F6 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 05, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 900 | $10.85 Strike: $10.85 | $9,765.00 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · derivative · entry 11 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,130 Underlying: Common Stock · 900 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. F6 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 05, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 54,560 | $50.00 | $2,728,000.00 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · nonDerivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. Read SEC document |
| October 05, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 54,560 | $10.85 | $591,976.00 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. Read SEC document |
| October 05, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 900 | $50.00 | $45,000.00 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. Read SEC document |
| October 05, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 900 | $10.85 | $9,765.00 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 50,000 | $10.85 Strike: $10.85 | $542,500.00 |
DisclosureSEC source: 0001070081-20-000120 · wf-form4_159501783961293.xml · derivative · entry 8 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,030 Underlying: Common Stock · 50,000 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. F6 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 50,000 | $10.85 Strike: $10.85 | $542,500.00 |
DisclosureSEC source: 0001070081-20-000120 · wf-form4_159501783961293.xml · derivative · entry 7 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,030 Underlying: Common Stock · 50,000 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. F6 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 24,401 | $55.93 | $1,364,747.93 |
DisclosureSEC source: 0001070081-20-000120 · wf-form4_159501783961293.xml · nonDerivative · entry 6 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $55.70 to $56.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 25,599 | $55.48 | $1,420,232.52 |
DisclosureSEC source: 0001070081-20-000120 · wf-form4_159501783961293.xml · nonDerivative · entry 5 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,486 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.70 to $55.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 50,000 | $10.85 | $542,500.00 |
DisclosureSEC source: 0001070081-20-000120 · wf-form4_159501783961293.xml · nonDerivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 24,403 | $55.94 | $1,365,177.03 |
DisclosureSEC source: 0001070081-20-000120 · wf-form4_159501783961293.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $55.69 to $56.58 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 25,597 | $55.48 | $1,419,993.58 |
DisclosureSEC source: 0001070081-20-000120 · wf-form4_159501783961293.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,488 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.69 to $55.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 50,000 | $10.85 | $542,500.00 |
DisclosureSEC source: 0001070081-20-000120 · wf-form4_159501783961293.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:05 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 33,788 | $10.85 Strike: $10.85 | $366,599.80 |
DisclosureSEC source: 0001070081-20-000102 · wf-form4_159017788583199.xml · derivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,030 Underlying: Common Stock · 33,788 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 5, 2020. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:05 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 33,788 | $50.00 | $1,689,400.00 |
DisclosureSEC source: 0001070081-20-000102 · wf-form4_159017788583199.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 5, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:05 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 33,788 | $10.85 | $366,599.80 |
DisclosureSEC source: 0001070081-20-000102 · wf-form4_159017788583199.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 5, 2020. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 6,284 | $10.85 Strike: $10.85 | $68,181.40 |
DisclosureSEC source: 0001070081-20-000100 · wf-form4_159000523971861.xml · derivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,818 Underlying: Common Stock · 6,284 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 5, 2020. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,284 | $50.12 | $314,979.22 |
DisclosureSEC source: 0001070081-20-000100 · wf-form4_159000523971861.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 5, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 6,284 | $10.85 | $68,181.40 |
DisclosureSEC source: 0001070081-20-000100 · wf-form4_159000523971861.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 5, 2020. Read SEC document |
| May 05, 2020 Filed May 7, 2020 19:44 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 109,928 | $10.85 Strike: $10.85 | $1,192,718.80 |
DisclosureSEC source: 0001070081-20-000097 · wf-form4_158888066893504.xml · derivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,102 Underlying: Common Stock · 109,928 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 5, 2020. F4 · derivative.exercise_date: This option was granted on May 15, 2013 and vests over four years, with 25% of the shares underlying the option vested on May 15, 2014 and an additional 2.083% of the original number of shares underlying the option vesting monthly thereafter beginning on June 15, 2014. Read SEC document |
| May 05, 2020 Filed May 7, 2020 19:44 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,985 | $51.01 | $101,252.87 |
DisclosureSEC source: 0001070081-20-000097 · wf-form4_158888066893504.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 5, 2020. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.00 to $51.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 05, 2020 Filed May 7, 2020 19:44 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 107,943 | $50.33 | $5,432,339.42 |
DisclosureSEC source: 0001070081-20-000097 · wf-form4_158888066893504.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,070 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 5, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 05, 2020 Filed May 7, 2020 19:44 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 109,928 | $10.85 | $1,192,718.80 |
DisclosureSEC source: 0001070081-20-000097 · wf-form4_158888066893504.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 5, 2020. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:41 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 28,600 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000048 · wf-form4_158050684896311.xml · derivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 28,600 Underlying: Common Stock · 28,600 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020 and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 29, 2021. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:41 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 192,500 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000048 · wf-form4_158050684896311.xml · derivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,500 Underlying: Common Stock · 192,500 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020 and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 29, 2021. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:41 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000048 · wf-form4_158050684896311.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 22,957 F1 · shares: Restricted stock units granted on January 29, 2020 that vest in four equal installments over four years, commencing on January 29, 2021. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:41 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000048 · wf-form4_158050684896311.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · shares: Restricted stock units granted on January 29, 2020 that vest in four equal installments over four years, commencing on January 29, 2021. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 423 | $53.25 | $22,523.48 |
DisclosureSEC source: 0001070081-20-000023 · wf-form4_158015950948844.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,102 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,115 shares of restricted stock from a January 22, 2019 grant of 4,620 shares of restricted stock. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 359 | $48.17 | $17,292.31 |
DisclosureSEC source: 0001070081-20-000011 · wf-form4_157852467459770.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,525 F4 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 975 RSUs from a January 3, 2017 grant of 3,900 RSUs. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 439 | $48.17 | $21,145.75 |
DisclosureSEC source: 0001070081-20-000011 · wf-form4_157852467459770.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,884 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,313 shares of restricted stock from a January 3, 2018 grant of 5,250 shares of restricted stock. F3 · balance_after: Includes 371 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2019 and 276 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2019. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,797 | $48.17 | $86,557.90 |
DisclosureSEC source: 0001070081-20-000011 · wf-form4_157852467459770.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,085 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 5,400 shares of restricted stock from a January 3, 2017 grant of 21,600 shares of restricted stock. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 7,656 | $18.01 Strike: $18.01 | $137,884.56 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · derivative · entry 19 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 22,969 Underlying: Common Stock · 7,656 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. F5 · derivative.exercise_date: This option was granted on January 3, 2018 and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 5,741 | $11.23 Strike: $11.23 | $64,471.43 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · derivative · entry 18 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 6,300 Underlying: Common Stock · 5,741 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. F4 · derivative.exercise_date: This option was granted on January 3, 2017 and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,000 | $12.64 Strike: $12.64 | $12,640.00 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · derivative · entry 17 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 875 Underlying: Common Stock · 1,000 shares Expires 2026-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. F3 · derivative.exercise_date: This option was granted on November 17, 2016 and vests over four years, with 25% of the shares underlying the option vesting on November 17, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on February 17, 2018. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 559 | $11.23 Strike: $11.23 | $6,277.57 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · derivative · entry 16 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,041 Underlying: Common Stock · 559 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. F4 · derivative.exercise_date: This option was granted on January 3, 2017 and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 125 | $12.64 Strike: $12.64 | $1,580.00 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · derivative · entry 15 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,875 Underlying: Common Stock · 125 shares Expires 2026-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. F3 · derivative.exercise_date: This option was granted on November 17, 2016 and vests over four years, with 25% of the shares underlying the option vesting on November 17, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on February 17, 2018. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 3,900 | $10.85 Strike: $10.85 | $42,315.00 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · derivative · entry 14 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 3,900 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,656 | $50.00 | $382,800.00 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · nonDerivative · entry 13 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,676 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,656 | $18.01 | $137,884.56 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · nonDerivative · entry 12 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 26,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,741 | $50.00 | $287,050.00 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · nonDerivative · entry 11 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,676 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 5,741 | $11.23 | $64,471.43 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · nonDerivative · entry 10 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 24,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,000 | $50.00 | $50,000.00 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · nonDerivative · entry 9 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,676 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,000 | $12.64 | $12,640.00 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · nonDerivative · entry 8 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 19,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 559 | $50.00 | $27,950.00 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · nonDerivative · entry 7 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,676 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 559 | $11.23 | $6,277.57 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · nonDerivative · entry 6 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 19,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:50 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 125 | $50.00 | $6,250.00 |
DisclosureSEC source: 0001070081-19-000059 · wf-form4_157558263765454.xml · nonDerivative · entry 5 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,676 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on March 13, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.